Xukang Medical·Yikon Genomics Closes ￥250 Million in Series D

(VCBeat) May. 6, 2021 -- Xukang Medical·Yikon Genomics announced today that it has secured 250 million yuan in a Series D round of financing. The existing investor CICC Qide Fund joins the new group of General Technology Venture Capital, YF Capital, Oriza Holdings and Jinli Fund General Venture Capital. The funds raised will be used for the technology research and development, clinical trials, sales channel expansion, marketing and clinical transformation of Xukang Medical·Yikon Genomics’ products in the field of reproductive health and tumor screening, diagnosis and treatment. The injection of money will also consolidate the leading position of Xukang Medical·Yikon Genomics in the field of assisted reproduction, and accelerate the clinical transformation of innovative gene testing technology in the field of reproductive health and tumor diagnosis.

Xukang Medical·Yikon Genomics was established in 2012. It is a high-tech enterprise dedicated to the development and application of single-cell whole-genome amplification and sequencing technologies, and provides precision medical detection technology for the fields of eugenics and early diagnosis of tumors.

Currently, Xukang Medical·Yikon Genomics includes Shanghai Xukang Medical Technology Co., Ltd., Shanghai Yikon Medical Laboratory Co., Ltd., Suzhou Yikon Medical Laboratory Co., Ltd. and Xukang Medical Technology (Suzhou) Co., Ltd and two offices located in Guangzhou and Wuhan.

Xukang Medical·Yikon Genomics strictly controlled the quality of products and testing services, which have passed ISO9001:2015 and ISO13485: 2016 International Quality Certification. Yikon Medical Laboratory obtained the "The Practice License of Medical Institution " approved by the Shanghai Municipal Health Commission, which permits to provide domestic and foreign medical institutions, scientific research institutes, groups and individuals with nearly a hundred types of testing services in fields of reproductive genetics, maternal and child health, tumor screening and life science research. In June 2017, Xukang Medical·Yikon Genomics PGS Kit passed the special approval of CFDA for innovative medical devices.

The preimplantation embryo genetic screening/diagnosis (PGS/PGD) service of Xukang Medical·Yikon Genomics can detect more than one hundred chromosomal genetic diseases and single-gene genetic diseases, and the cumulative number of services has exceeded 10,000.

The MALBAC^® single-cell genome amplification technology developed by Xukang Medical·Yikon Genomics is widely used in preimplantation embryo genetic testing (PGT). It is able to block the familial transmission of more than 600 single-gene genetic diseases, including nearly 20 kinds of inherited tumors, helping hundreds of thousands of patients to give birth to healthy infants.

GTVC was registered in March 2012, formerly the Equity Investment Department of Genertec Investment. The registered address is Zhongguancun Science and Technology Park, Haidian District, Beijing. The company's registered capital is RMB 200 million. It is the venture capital arm of Genertec Investment focusing on growth-stage startups.

The investment management team of GTVC has more than ten years of experience in professional investment in the fields of financial services, health care, information technology, new materials, equipment manufacturing, etc.

Founded in 2010, YF Capital is a leading private equity firm in China. YF Capital currently manages multiple USD and RMB funds. The company has formed deep sector expertise and industry insights in our focused sectors, including internet, technology, healthcare, entertainment, consumer, finance and logistics.